

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Jack TAUNTON, et al.

U.S. Application No.: 10/552,847

Int'l Application No.: PCT/US04/011297

Int'l Filing Date: April 12, 2004

For: SELECTIVE SERINE/  
THREONINE KINASE INHIBITORS

Confirmation No.: 2596

Examiner: Not Yet Assigned

Art Unit:

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR §1.97 and  
§1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references, in compliance with the requirements of 37 CFR §1.98(a)(2), are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of the Search/Examination report corresponding to the PCT application.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the

Jack TAUNTON, et al.  
Application No.: 10/552,847  
Page 2

PATENT

undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Joel G. Ackerman  
Reg. No. 24,307

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
JA:sba  
60793114 v1

Substitute for form 1449A&B/PTO				Complete If Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/552,847
				Filing Date	April 12, 2004
				First Named Inventor	TAUNTON, Jack
				Art Unit	1624
				Examiner Name	<del>Not Yet Assigned</del> Kifle
Sheet	1	of	2	Attorney Docket Number	018062-006210US

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
/BK/ ↓ ↓ ↓ ↓ ↓	AA	US 5,844,106	12-01-1998	Seela et al.		
	AB	US 2002/0013354 A1	01-31-2002	Cheng et al.		
	AC	US 6,376,527 B1	04-23-2002	Goldstein et al.		
	AD	US 2002/0103245 A1	08-01-2002	Goldstein et al.		
	AE	US 2002/0156114 A1	10-24-2002	Goldstein et al.		
	AF	US 2003/0018051 A1	01-23-2003	Goldstein et al.		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
/BK/ ↓ ↓ ↓	AG	WO	99/06396	A1	02-11-1999			<input type="checkbox"/>
	AH	WO	97/38983	A1	10-23-1997			<input type="checkbox"/>
	AI	WO	00/31048	A1	06-02-2000			<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
/BK/ ↓ ↓ ↓ ↓	AJ	ABIRU, Seigou et al.; "Aspirin and NS-398 Inhibit Hepatocyte Growth Factor-Induced Invasiveness of Human Hepatoma Cells"; 2002, <u>Hepatology</u> , Vol. 35, No. 5, pp. 1117-1124.			<input type="checkbox"/>
	AK	BURCHAT, A.F., et al.; "Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of Ick II"; <u>Bioorganic &amp; Medicinal Chemistry Letters</u> ; October 2, 2000; pp. 2171-2174; Vol. 10, No. 19.			<input type="checkbox"/>
	AL	CHENON, M.T., et al.; "Carbon-13 magnetic resonance. XXV. Basic set of parameters for the investigation of tautomerism in purines established from carbon-13 magnetic resonance studies using certain purines and pyrrolo[2,3-d]pyrimidines."; <u>Journal of the American Chemical Society</u> ; 1975; pp. 4627-4636; Vol. 97, No. 16.			<input type="checkbox"/>
	AM	DAVE, Chaitanya G. et al.; "Synthesis & Biological Activity of Pyrrolo[2,3-d]pyrimidines"; 1988, <u>Indian Journal of Chemistry</u> , Vol. 27B, pp. 778-780.			<input type="checkbox"/>

Examiner Signature	/Bruck Kifle/ (04/25/2008)	Date Considered	04/25/2008
--------------------	----------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/552,847
		Filing Date	April 12, 2004
		First Named Inventor	TAUNTON, Jack
		Art Unit	1624
		Examiner Name	<del>Not Yet Assigned</del> Kifle
		Attorney Docket Number	018062-006210US
Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/BK/ ↓	AN	HANKE, Jeffrey H. et al.; "Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor"; 1996, <u>The Journal of Biological Chemistry</u> , Vol. 271, No. 2, pp. 695-701.	<input type="checkbox"/>
	AO	LIU, Yi et al.; "Structural basis for selective inhibition of Src family kinases by PP1"; 1999, <u>Chemistry &amp; Biology</u> , Vol. 6, No. 9, pp. 671-678.	<input type="checkbox"/>
	AP	SCHINDLER, Thomas et al.; "Crystal Structure of Hck in Complex with a Src Family-Selective Tyrosine Kinase Inhibitor"; 1999, <u>Molecular Cell</u> , Vol. 3, pp. 639-648.	<input type="checkbox"/>
	AQ	STEVENSON, Mary Ann et al.; "Salicylic Acid and Aspirin Inhibit the Activity of RSK2 Kinase and Repress RSK2-Dependent Transcription of Cyclic AMP Response Element Binding Protein- and NF- $\kappa$ B-Responsive Genes"; 1999, <u>The Journal of Immunology</u> , pp. 5608-5616.	<input type="checkbox"/>
	AR	TATTON, Louise et al.; "The Src-selective Kinase Inhibitor PP1 Also Inhibits Kit and Bcr-Abl Tyrosine Kinases"; 2003, <u>The Journal of Biological Chemistry</u> , Vol. 278, No. 7, pp. 4847-4853.	<input type="checkbox"/>
	AS	ZHU, Xiaotian et al.; "Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors"; 1999, <u>Structure</u> , Vol. 7, No. 6, pp. 651-661.	<input type="checkbox"/>

Examiner Signature	/Bruck Kifle/ (04/25/2008)	Date Considered	04/25/2008
--------------------	----------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant to place a check mark here if English language Translation is attached.